Unpacking Merck & Co. – Key Stock Insights

By Tamara Parker • Tuesday, February 04 10:13 • Permanent Link

Large-cap Health Care company Merck & has moved -10.5% so far today on a volume of 15,952,868, compared to its average of 11,649,400. In contrast, the S&P 500 index moved 0.0%.

Merck & trades -27.77% away from its average analyst target price of $123.63 per share. The 24 analysts following the stock have set target prices ranging from $100.0 to $150.0, and on average have given Merck & a rating of buy.

Anyone interested in buying MRK should be aware of the facts below:

Merck &'s current price is 1209.4% above its Graham number of $6.82, which implies that at its current valuation it does not offer a margin of safety
Merck & has moved -21.4% over the last year, and the S&P 500 logged a change of 21.0%
Based on its trailing earnings per share of 4.78, Merck & has a trailing 12 month Price to Earnings (P/E) ratio of 18.7 while the S&P 500 average is 29.3
MRK has a forward P/E ratio of 9.5 based on its forward 12 month price to earnings (EPS) of $9.4 per share
Its Price to Book (P/B) ratio is 5.08 compared to its sector average of 3.53
Merck & Co., Inc. operates as a healthcare company worldwide.
Based in Rahway, the company has 70,000 full time employees and a market cap of $225.9 Billion. Merck & currently returns an annual dividend yield of 3.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.